{"id":"W3149611511","doi":"10.1093/ecco-jcc/jjab058","title":"Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"Research Canada; Covenant Health; University of Toronto; Grey Nuns Community Hospital; Mount Sinai Hospital; St. Paul's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Takeda Pharmaceutical Company","keywords":"Medicine; Vedolizumab; Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Tumor necrosis factor alpha; Inflammatory Bowel Diseases; Tumor necrosis factors; Infliximab; Internal medicine; Disease; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003498352,0.0001928092,0.0006242998,0.0003718392,0.0001660401,0.0006806316,0.0002377688,0.0003907756,0.0005980785],"category_scores_gemma":[0.005958184,0.0001115241,0.0008119614,0.0005267183,0.0002366985,0.0004302274,0.0004845019,0.0003489981,0.0001019099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005725657,"about_ca_system_score_gemma":0.0004077189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001943558,"about_ca_topic_score_gemma":0.002330285,"domain_scores_codex":[0.9979165,0.001136124,0.0002106294,0.0002065285,0.0004157049,0.000114471],"domain_scores_gemma":[0.9938343,0.00194815,0.0028827,0.000352118,0.0004728272,0.0005099212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01980212,0.0007601103,0.9606827,0.0001782659,0.001412958,0.0000939666,0.0001853962,0.0004146384,0.0003667364,0.000075477,0.0002677107,0.01575985],"study_design_scores_gemma":[0.001241752,0.00366406,0.9924086,0.00003966631,0.0005856773,0.0002547157,0.0001494574,0.0005512195,0.0001988053,0.00003002233,0.0008624406,0.00001358955],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985493,0.0007860746,0.0000534731,0.00003312956,0.000003564879,0.000019943,0.0002637453,0.000001708722,0.0002890337],"genre_scores_gemma":[0.9985109,0.000350007,0.0001130099,0.00005030197,0.00001893741,0.00001885153,0.0008420244,0.000001654423,0.00009439007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003498352,"threshold_uncertainty_score":0.01850122,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01066192318520401,"score_gpt":0.250891219267981,"score_spread":0.240229296082777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}